Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IDE drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IDE Recombinant Protein (Wild Type & Catalytically Inactive E111Q Mutant) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for SPR/BLI binding assays. |
View IDE Products |
| Gene Delivery | IDE Promise-ORF / Lentivirus Full-length human IDE ORF for stable cell line construction and cell-based degradation assays. |
View IDE Products |
| Benchmark Ab | Anti-IDE Recombinant Monoclonal Antibody Recombinant positive control for western blot, ELISA, and immunoprecipitation. |
View IDE Products |
| Validator | IDE siRNA Set Target-specific siRNA pool for gene knockdown validation in functional assays. |
View IDE Products |
| Related Target A | MME (Neprilysin) Critical off-target counter-screening metalloprotease. Sharing overlapping substrates like Amyloid-beta. |
View MME Products |
| Related Target B | INS (Insulin) Primary physiological substrate of IDE. Essential for downstream activity and competition assays. |
View INS Products |
| Related Target C | APP (Amyloid Beta) Pathological substrate cleared by IDE. Crucial for neurodegenerative disease modeling. |
View APP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Screening (MME/Neprilysin cross-reactivity) | Highly purified recombinant Human MME and ECE1 proteins available for rigorous selectivity profiling. |
| Conformational Binding Verification (Active vs. Inactive State) | Catalytically inactive IDE (E111Q) mutant available to isolate binding affinity from substrate cleavage events. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and validated positive control siRNA included in the catalog. |
| False Positives in Small Molecule Screens | Endotoxin-controlled, mammalian-expressed (HEK293) proteins ensure native folding and minimize non-specific interactions. |
Live IDE R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Insulin-Degrading Enzyme (IDE) represents a delicate balancing act between endocrinology and neurology. As a zinc-metalloprotease responsible for degrading both insulin and amyloid-beta (Aβ), IDE is a highly sought-after target for Type 2 Diabetes (T2D) and Alzheimer's Disease (AD). The race for IDE therapeutics is intensifying, with major players shifting focus from traditional systemic inhibitors to tissue-selective small molecules and allosteric modulators. As first-generation systemic therapies reach the clinic, the next wave of R&D is targeting substrate-selective modulation—inhibiting insulin degradation while sparing or enhancing Aβ clearance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academics / Biotech Consortia | Type 2 Diabetes (T2D) | Selectivity Assay (Need Mutant vs WT Proteins & MME counter-screening) |
| Allosteric Modulator (Activator) | Neuro-therapeutics Startups | Alzheimer's Disease (AD) | Conformational Stability (Need high-purity HEK293-expressed IDE) |
| Peptide Therapeutics | Mid-size Pharma | Metabolic Disorders | Substrate Competition Assays (Need high-purity INS and APP reagents) |